[go: up one dir, main page]

PE20020665A1 - ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3 - Google Patents

ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3

Info

Publication number
PE20020665A1
PE20020665A1 PE2001000575A PE2001000575A PE20020665A1 PE 20020665 A1 PE20020665 A1 PE 20020665A1 PE 2001000575 A PE2001000575 A PE 2001000575A PE 2001000575 A PE2001000575 A PE 2001000575A PE 20020665 A1 PE20020665 A1 PE 20020665A1
Authority
PE
Peru
Prior art keywords
alkyl
ring
cycloalkyl
ovß3
phenyl
Prior art date
Application number
PE2001000575A
Other languages
English (en)
Inventor
Michael Clare
Alan F Gasiecki
Ish Kumar Khanna
Thomas Rogers
Mark Russell
Barbara B Chen
Hwang-Fun Lu
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of PE20020665A1 publication Critical patent/PE20020665A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS ACIDO CICLOALQUIL FENIL ALCANOICO DE FORMULA I DONDE EL ANILLO A ES UN ANILLO MONOCICLICO DE 4-8 MIEMBROS, ANILLO BICICLICO DE 7-12 MIEMBROS; A1 ES UN ANILLO MONOCICLICO DE 5-9 MIEMBROS, HETEROCICLO POLICICLICO DE 7-14 MIEMBROS, NR5-C(=Y1)-NR8R7, NR5C(Y2)(=NR7); CUANDO Z1 ES CO, SO2, EL ENLACE A1-Z2 INCLUYE PIRIDINA, IMIDAZOL, TIAZOL, OXAZOL, BENZIMIDAZOL, IMIDAZOPIRIDINA; Y1 ES NR2, O, S; R2 ES H, ALQUILO, ARILO, OH, ALCOXI; R7 Y R8 SON H, ALQUILO, ARALQUILO, AMINO, ALQUILAMINO; NR7 Y R8 FORMAN UN ANILLO MONOCICLICO, BICICLICO; R5, Rm, Rp, Rk, Rf SON H, ALQUILO; A ES NR5C(Y)=NR'; Y2 ES ALQUILO, CICLOALQUILO, BICICLOALQUILO, ENTRE OROS; Z1 ES CH2, O, NH, NRk, ENTRE OTROS; Z2 ES UN ENLAZANTE C2-C5; Z1-Z2 CONTIENE ADEMAS CARBOXAMIDA, SULFONA, ENLAZADO AL ANILLO A EN POSICION PARA O META EN RELACION A X1; n ES 0-1; Rc ES H, ALQUILO, HALOGENO, OH, ENTRE OTROS; X1 ES O, CO, SO2, NRm, (CHRp)q; Rp ES H, ALQUILO, ALCOXI, OH; q ES 0-1; X2 ES CHRe, CO, SO2, NRf, S. X o Y ES CRg, N; Rg ES H, ALQUILO, HALOALQUILO, FLUORO, ENTRE OTROS, X-X2-Y CONTIENE ACILO, ALQUILO, AMINO, ENTRE OTROS; Rb ES X3-Rh; X3 ES O, S, NRj; Rj Y Rh SON H, ALQUILO, ACILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS ACIDO 2-[4-[3-(2-PIRIDINILAMINO)PROPOXI]FENIL]CICLOPROPANO-ACETICO, ENTRE OTROS. LOS COMPUESTOS SON ANTAGONISTAS DE INTEGRINAS OVß3 Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE METASTASIS TUMORAL, CRECIMIENTO TUMORAL, OSTEOPOROSIS, ENFERMEDAD DE PAGET, RETINOPATIA, DEGENERACION MACULAR
PE2001000575A 2000-06-15 2001-06-15 ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3 PE20020665A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21178100P 2000-06-15 2000-06-15

Publications (1)

Publication Number Publication Date
PE20020665A1 true PE20020665A1 (es) 2002-08-14

Family

ID=22788343

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000575A PE20020665A1 (es) 2000-06-15 2001-06-15 ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3

Country Status (8)

Country Link
US (2) US6900232B2 (es)
EP (1) EP1289960A2 (es)
JP (1) JP2004525069A (es)
AR (1) AR030701A1 (es)
AU (1) AU2001269821A1 (es)
PE (1) PE20020665A1 (es)
UY (1) UY26780A1 (es)
WO (1) WO2001096307A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
ATE438401T1 (de) * 2002-06-12 2009-08-15 Chemocentryx Inc 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US20040259669A1 (en) * 2003-06-20 2004-12-23 Seaway Plastics Ltd. Volleyball net pretensioned with rigid side strips
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
JP4845873B2 (ja) * 2004-03-03 2011-12-28 ケモセントリックス インコーポレーティッド 二環式および架橋した窒素複素環
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
EP2394662B1 (en) 2004-04-02 2018-03-21 The Regents of The University of California Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
EP1836169B9 (en) 2004-12-28 2012-07-04 Kinex Pharmaceuticals, LLC Compositions and methods of treating cell proliferation disorders
US8399489B2 (en) 2005-02-18 2013-03-19 Astrazeneca Ab Antibacterial piperdine derivatives
AU2007265373B2 (en) 2006-06-29 2013-02-21 Atnx Spv, Llc Biaryl compositions and methods for modulating a kinase cascade
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
HRP20120948T1 (hr) 2007-10-09 2012-12-31 Merck Patent Gmbh Derivati piridina koji su korisni kao aktivatori glukokinaze
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
BR112012001463A2 (pt) 2009-07-24 2016-03-15 Univ California métodos e composições para tratar e prevenir doença associada à integrina alfavbeta5
CA2796419C (en) 2010-04-16 2018-11-06 Kinex Pharmaceuticals, Llc Compositions and methods for the prevention and treatment of cancer
HUE037637T2 (hu) 2012-08-30 2018-09-28 Athenex Inc N-(3-fluorobenzil)-2-(5-(4-morfolinofenil)piridin-2-IL) acetamid, mint fehérje tirozin kináz modulátorok
SI3929196T1 (sl) 2013-09-24 2023-11-30 Fujifilm Corporation Farmacevtska sestava spojine, ki vsebuje dušik ali njegovo sol ali njegov kovinski kompleks
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
CN116041169B (zh) * 2022-07-29 2025-10-24 北京先通国际医药科技股份有限公司 一种合成修饰脂肪酸型pet试剂前体关键中间体的工艺路线及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654306A (en) * 1970-01-26 1972-04-04 Robins Co Inc A H 5-azaspiro(2.4)heptane-4 6-diones
IL99537A (en) 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
GB9202792D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
WO1993021166A1 (en) 1992-04-10 1993-10-28 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type ii-diabetes
GB9311282D0 (en) 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd New compositions of matter
GB9315148D0 (en) 1993-07-22 1993-09-08 Smithkline Beecham Plc Novel compounds
US5665754A (en) 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE4408082A1 (de) 1994-03-10 1995-09-14 Hoechst Ag Substituierte Propan-Derivate, Verfahren zu ihrer Herstellung und die Anwendung der Verbindungen zur Behandlung von Krankheiten
WO1995032710A1 (en) 1994-05-27 1995-12-07 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption
US5710171A (en) * 1995-05-24 1998-01-20 Merck & Co., Inc. Bisphenyl inhibitors of farnesyl-protein transferase
CA2176854A1 (en) * 1995-06-07 1996-12-08 Daniel J. Keavy N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
DE19536891A1 (de) 1995-10-04 1997-04-10 Basf Ag Neue Aminosäurederivate, ihre Herstellung und Verwendung
IT1276153B1 (it) * 1995-11-17 1997-10-27 Roberto Pellicciari Derivati di glicina ad attivita' antagonista dei recettori metabotropi del glutammato
PT889875E (pt) * 1996-03-29 2001-10-30 Searle & Co Derivados de acidos ciclopropilalcanoicos
ATE219764T1 (de) * 1996-03-29 2002-07-15 Searle & Co Zimtsäurederivate und deren verwendung als integrin-antagonisten
EP0889877B1 (en) 1996-03-29 2001-08-29 G.D. Searle & Co. META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS
US6121288A (en) 1996-11-08 2000-09-19 Nippon Chemiphar Co., Ltd. Visceral fat lowering agent
AU729869B2 (en) 1997-01-17 2001-02-15 Merck & Co., Inc. Integrin antagonists
JPH10287634A (ja) 1997-04-11 1998-10-27 Otsuka Pharmaceut Co Ltd ベンゼン誘導体
TR200002625T2 (tr) 1998-03-10 2000-12-21 Smithkline Beecham Corporation Vitronektin Reseptörü Antagonistleri
UA71586C2 (en) * 1998-12-04 2004-12-15 Smithkline Beecham Corp A vitronectin receptor antagonist
AU783992B2 (en) 1998-12-23 2006-01-12 G.D. Searle Llc Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1177187B1 (en) 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
WO2000068195A2 (en) * 1999-05-05 2000-11-16 Aventis Pharma Limited Substituted pyrrolidines as cell adhesion inhibitors
DE19939980A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
DE19939981A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Neue Inhibitoren des Integrins alphavß3

Also Published As

Publication number Publication date
JP2004525069A (ja) 2004-08-19
AR030701A1 (es) 2003-09-03
US20040259869A1 (en) 2004-12-23
UY26780A1 (es) 2002-01-31
EP1289960A2 (en) 2003-03-12
US6900232B2 (en) 2005-05-31
WO2001096307A3 (en) 2002-08-15
WO2001096307A2 (en) 2001-12-20
US20020077321A1 (en) 2002-06-20
AU2001269821A1 (en) 2001-12-24
US6949578B2 (en) 2005-09-27

Similar Documents

Publication Publication Date Title
PE20020665A1 (es) ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
EA200400830A1 (ru) ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ, ОТНОСЯЩИЕСЯ К A2b-СЕЛЕКТИВНЫМ АНТАГОНИСТАМ, ИХ СИНТЕЗ И ПРИМЕНЕНИЕ
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
PE20020917A1 (es) Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato
RU2010131833A (ru) Способы получения производных хиназолинона
PE20050765A1 (es) DERIVADOS DE SULFONAMIDA COMO AGONISTAS DE LOS RECEPTORES ß2 ADRENERGICOS
PE58399A1 (es) Atropisomeros de 3-aril-4(3h)-quinazolinonas
DE60228406D1 (de) PYRAZOLOÄ3,4-dÜPYRIMIDINDERIVATE UND IHRE VERWENDUNG ALS ANTAGONISTEN DES PURINERGEN REZEPTORS
PE20051046A1 (es) Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
PE20120814A1 (es) Compuestos y composiciones como inhibidores de la proteina cinasa
PE20010219A1 (es) AGONISTAS ß-ADRENORRECEPTORES
JP2005508966A5 (es)
PE20051136A1 (es) Derivados de sulfonamida
CA2078810A1 (en) Leukotriene biosynthesis inhibitors
PE20060693A1 (es) Nuevos derivados de trifluorometansulfonanilida oxamida eter
JP2005509622A5 (es)
PE20020483A1 (es) Peptidos ciclicos selectivos como agonistas de los receptores de melanocortina 4
PE20010753A1 (es) DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a
JPH04330073A (ja) アンギオテンシンｉｉ拮抗薬としての置換ピリドピリミジノン類及び関連複素環類
CA2624602A1 (en) Process for preparing 6-substituted-7-azaindoles
PE20070004A1 (es) Imidazoquinolinas como inhibidores de quinasa de lipido
PE20021158A1 (es) Derivados de sulfonamida como antagonistas del receptor de bradiquinina
CN1152872A (zh) 噻唑和噻二唑化合物作为d3多巴胺受体配位体的应用

Legal Events

Date Code Title Description
FC Refusal